AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Promethera Biosciences to Attend and Present at Upcoming Scientific and Partnering Conferences in March and April

March 12, 2019

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Mar 12, 2019--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that the Company will give presentations and attend the following scientific and partnering conferences in Japan, Europe, and the US.

18 th Congress of the Japanese Society for Regenerative Medicine
Date: March 21-23, 2019
Venue: JSRM Convention Center, Kobe, Japan
Breakfast seminar on liver regeneration by allogenic mesenchymal stem cell therapy:

Session 1: Mesenchymal stem cells derived from adult human liver: an attractive expandable cell source to target hepatic deficiencies
Presenter: Mustapha Najimi, Special Advisor – Scientific Affairs

Session 2: HepaStem, adult liver mesenchymal stem cells for liver rescue therapy in ACLF and NASH
Presenter: Prof. Etienne Sokal, M.D., Ph.D., CMO/CSO
Date: March 23 rd, 2019

BioEurope Spring
Date: March 25-27, 2019
Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria
Panel:

Title: “What’s NEXT in NASH?”
Presenter: Pascale Jordan, Ph.D. Director BD, External Evaluation
Date: March 25 th, 2019

The International Liver Congress™ 2019 (EASL)
Date: April 10-14, 2019
Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria
Booth: Biotech Village booth #6

3 rd  Annual NASH Summit in Boston
Date: April 22-25, 2019
Venue: Hilton Boston Logan Airport, Boston, MA, USA
Presentation:

Title: “HepaStem for the treatment of fibro-inflammatory liver diseases”
Date: April 22, 2019
Presenter: Nathalie Belmonte, Ph.D., VP Product Development

Cell & Gene Meeting on the Mediterranean
Date: April 23-25, 2019
Venue: Hotel Arts Barcelona, Barcelona, Spain
Panel:

Title: “Recent developments and predictions for the future of advanced therapies”
Presenter: John Tchelingerian, Ph.D., President & CEO

Company presentation:

Title: “HepaStem, adult liver medicinal signaling cells for liver rescue therapy in ACLF and NASH”
Presenter: Prof. Etienne Sokal, M.D., Ph.D., CMO/CSO
Date: April 24 rd, 2019

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA group.

https://www.linkedin.com/company/promethera-biosciences

https://twitter.com/Promethera

View source version on businesswire.com:https://www.businesswire.com/news/home/20190312005122/en/

CONTACT: Promethera Biosciences SA

Alexandra Schiettekatte

Alexandra.schiettekatte@promethera.com

Web:www.promethera.comFor media:

MacDougall Communications

Mario Brkulj or Shai Biran, Ph.D.

+49 89 2420 9345

or +1 781-235-3060

promethera@macbiocom.com

KEYWORD: BELGIUM EUROPE

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL GENERAL HEALTH

SOURCE: Promethera Biosciences

Copyright Business Wire 2019.

PUB: 03/12/2019 04:00 AM/DISC: 03/12/2019 04:01 AM

http://www.businesswire.com/news/home/20190312005122/en